Corvus Pharmaceuticals, Inc.
CRVS
$14.07
-$0.01-0.07%
NASDAQ
| 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | 12/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -21.31% | -26.99% | -152.64% | 225.43% | 69.88% |
| Total Depreciation and Amortization | -7.14% | -3.45% | 31.82% | 10.00% | -4.76% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 81.49% | 258.77% | 97.03% | -564.52% | -84.92% |
| Change in Net Operating Assets | 297.09% | -119.01% | 1,803.29% | 110.42% | -1,157.25% |
| Cash from Operations | 3.92% | -65.59% | 30.09% | 2.39% | -33.92% |
| Capital Expenditure | -- | 100.00% | -213.89% | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 516.54% | 87.03% | -571.79% | 170.29% | -56.50% |
| Cash from Investing | 515.58% | 87.10% | -578.46% | 169.75% | -56.38% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -94.44% | -98.99% | 12,720.79% | -98.50% | 37,116.00% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -94.44% | -98.99% | 12,720.79% | -98.50% | 37,116.00% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 114.45% | -222.00% | 359.08% | -192.14% | 139.96% |